Among KTRs with T2D taking any GLMs, most patients were prescribed insulin (75%), followed by second-generation SU (21.9%), metformin (21.8%), DPP4i (16.1%), GLP1RA (11.5%), SGLT2i (8.1%), and TZD (3.9%). This evidence concerns the gene INS and type 2 diabetes mellitus.